- Home
- CDRE vs JANX Comparison
CDRE vs JANX Comparison
Compare CDRE & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CDRE
- JANX
- Stock Information
- Founded
- CDRE 2012
- JANX 2017
- Country
- CDRE United States
- JANX United States
- Employees
- CDRE N/A
- JANX N/A
- Industry
- CDRE Industrial Specialties
- JANX Biotechnology: Pharmaceutical Preparations
- Sector
- CDRE Health Care
- JANX Health Care
- Exchange
- CDRE Nasdaq
- JANX Nasdaq
- Market Cap
- CDRE 1.3B
- JANX 1.4B
- IPO Year
- CDRE 2021
- JANX 2021
- Fundamental
- Price
- CDRE $37.60
- JANX $22.42
- Analyst Decision
- CDRE Buy
- JANX Strong Buy
- Analyst Count
- CDRE 2
- JANX 11
- Target Price
- CDRE $31.50
- JANX $76.55
- AVG Volume (30 Days)
- CDRE 317.3K
- JANX 761.7K
- Earning Date
- CDRE 11-05-2025
- JANX 11-05-2025
- Dividend Yield
- CDRE 1.01%
- JANX N/A
- EPS Growth
- CDRE N/A
- JANX N/A
- EPS
- CDRE 0.93
- JANX N/A
- Revenue
- CDRE $572,607,000.00
- JANX $439,000.00
- Revenue This Year
- CDRE $12.55
- JANX N/A
- Revenue Next Year
- CDRE $7.70
- JANX $130.50
- P/E Ratio
- CDRE $40.41
- JANX N/A
- Revenue Growth
- CDRE 7.66
- JANX N/A
- 52 Week Low
- CDRE $27.07
- JANX $21.73
- 52 Week High
- CDRE $40.28
- JANX $71.71
- Technical
- Relative Strength Index (RSI)
- CDRE 70.09
- JANX 43.25
- Support Level
- CDRE $35.44
- JANX $23.00
- Resistance Level
- CDRE $36.68
- JANX $24.57
- Average True Range (ATR)
- CDRE 1.11
- JANX 1.22
- MACD
- CDRE 0.15
- JANX -0.02
- Stochastic Oscillator
- CDRE 93.48
- JANX 19.78
About CDRE Cadre Holdings Inc.
Cadre Holdings Inc is engaged in the design and manufacture of a diversified product portfolio of critical safety and survivability equipment to protect first responders, federal agencies, outdoor recreation, and personal protection markets. The Company's equipment provides critical protection to allow its users to safely and securely perform their duties and protect those around them in hazardous or life-threatening situations. Its operations are comprised of two reportable segments: Products and Distribution.
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.